Compare Sana Biotechnology Inc (SANA) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Sana Biotechnology Inc trades at $3.24 (market cap $1.03B), while iShares 20 Plus Year Treasury Bond ETF trades at $81.78. The key difference: Sana Biotechnology Inc is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| SANA | TLT | |
|---|---|---|
Market Cap | $1.03B | — |
Sector | Health | — |
52-Week High | $5.92 | $92.06 |
52-Week Low | $2.68 | $81.35 |
Enterprise Value | $946.04M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $82.2 with minimal daily change. Technical signals are bearish, with moving averages indicating selling pressure and oscillators neutral. Recent Treasury buyback announcements and rising global bond yields create a volatile backdrop. The ETF continues its dividend distributions, with recent payments around $0.32 per share.
Outlook remains cautious amid rising interest rate expectations and inflation concerns. Investment opportunity exists for long-term income seekers, but risks include further yield increases and potential large-scale Treasury selling by institutional investors like Norway's sovereign fund.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
